STAT3 has been shown to be required for synoviocyte survival in RA (Krause et al., 2002), and STAT3 inhibitors have been proposed as therapeutic candidates for RA treatment (Oike et al., 2017). The gene discussed is STAT3; the disease is rheumatoid arthritis.